Abstract
The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.
Keywords: Basal cell carcinoma, gli, hedgehog signaling, medulloblastoma, smoothened, synthetic small molecules.
Current Medicinal Chemistry
Title:Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Volume: 22 Issue: 35
Author(s): C.A. Maschinot, J.R. Pace and M.K. Hadden
Affiliation:
Keywords: Basal cell carcinoma, gli, hedgehog signaling, medulloblastoma, smoothened, synthetic small molecules.
Abstract: The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.
Export Options
About this article
Cite this article as:
Maschinot C.A., Pace J.R. and Hadden M.K., Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics, Current Medicinal Chemistry 2015; 22 (35) . https://dx.doi.org/10.2174/0929867322666150827093904
DOI https://dx.doi.org/10.2174/0929867322666150827093904 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of miRNAs in Cartilage Homeostasis
Current Genomics Telocytes as a Source of Progenitor Cells in Regeneration and Repair Through Granulation Tissue
Current Stem Cell Research & Therapy Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses
Anti-Cancer Agents in Medicinal Chemistry Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Apoptosis in Physiological and Pathological Skin: Implications for Therapy
Current Molecular Medicine Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery New Advances in the Pathogenesis and Progression of Barrett’s Esophagus
Current Molecular Medicine The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets